Moinuddin Mokhashi
Pediatric Endocrinology · Newhall, CANPI 1821157298
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,476 of the $16,393 with a category attached, or 63.9%. Sanofi-aventis U.S. LLC accounts for 67.5% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $12,390, more than ten times the $313 reported in 2019.
Across 245 payments — averaging $66.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$11K
- AbbVie$1K
- Novo Nordisk$865
- Xeris Pharmaceuticals, Inc.$289
- Rhythm Pharmaceuticals, Inc.$279
- Biomarin Pharmaceutical Inc.$275
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$10,47664%
- Food & beverage$5,62334%
- Education$2942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 21 | $11,060 |
| AbbVie | 58 | $1,133 |
| Novo Nordisk | 24 | $865 |
| Xeris Pharmaceuticals, Inc. | 13 | $289 |
| Rhythm Pharmaceuticals, Inc. | 12 | $279 |
| Biomarin Pharmaceutical Inc. | 10 | $275 |
| Pfizer | 16 | $270 |
| Ascendis Pharma Endocrinology Inc | 12 | $262 |
| Lilly USA, LLC | 12 | $237 |
| Kyowa Kirin, Inc. | 3 | $194 |
| Abbott | 4 | $193 |
| Cequr Corporation | 2 | $164 |
| Tandem Diabetes Care, Inc. | 6 | $162 |
| Ultragenyx Pharmaceutical Inc. | 6 | $121 |
| Tolmar, Inc. | 5 | $119 |
| Arbor Pharmaceuticals, Inc. | 6 | $107 |
| Dexcom, Inc. | 6 | $92 |
| Cranial Technologies, Inc | 4 | $69 |
| Medtronic | 4 | $69 |
| Ferring Pharmaceuticals Inc. | 3 | $61 |
| Insulet Corporation | 2 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Merck | 2 | $38 |
| Tolmar Pharmaceuticals, Inc. | 1 | $29 |
| Soleno Therapeutics, Inc. | 1 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $27 |
| UCB, Inc. | 1 | $27 |
| Eton Pharmaceuticals, Inc. | 1 | $21 |
| Vistapharm, Inc. | 1 | $18 |
| GSK | 1 | $18 |
| Immedica Pharma US, Inc. | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$10,706
- Lupron Depot$211
- CRYSVITA$140
- Sogroya$120
- CeQur Simplicity$109
- FREESTYLE LIBRE 3$109
How this compares
$16,393 in reported general payments places this provider in the 85th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Newhall
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Lynda PolgreenOrange$167K
- Kevin KaisermanWest Covina$150K
- Amrit BhangooLong Beach$140K
- Mitchell GeffnerLos Angeles$129K
- Stephen GitelmanSan Francisco$105K
- David MaahsStanford$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.